GlassScriptPhysician profile
Marie E Garrity
NPI 1629066584
$7,416.78
in general payments reported to CMS, 2019-2025
37 companies · $967 in 2025
The $967 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $1,034 · 2021: $897 · 2022: $1,372 · 2023: $1,303 · 2024: $697 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,083.62 | 2019-2025 | Evenity, Prolia, Enbrel |
| Abbvie INC. | $954.43 | 2019-2024 | |
| Lilly USA, LLC | $586.13 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novartis Pharmaceuticals Corporation | $502.04 | 2019-2025 | |
| Novo Nordisk INC | $368.83 | 2021-2025 | Ozempic, Rybelsus |
| Ucb, INC. | $367.17 | 2019-2023 | Cimzia |
| Pfizer INC. | $323.17 | 2019-2025 | |
| Horizon Therapeutics Plc | $320.32 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $253.94 | 2020-2023 | Acthar |
| Janssen Biotech, INC. | $227.81 | 2019-2023 | Remicade, Stelara, Simponi Aria |
| Exact Sciences Corporation | $158.62 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $156.24 | 2019-2025 | Veozah |
| Esperion Therapeutics, INC. | $136.39 | 2024-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $133.45 | 2022-2025 | Farxiga, Saphnelo, Airsupra |
| Madrigal Pharmaceuticals | $107.81 | 2025 | Rezdiffra |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $80.64 | 2022-2023 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $66.10 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Celgene Corporation | $63.06 | 2019 | |
| Sobi, INC | $62.92 | 2019-2020 | |
| Radius Health, INC. | $61.14 | 2019-2022 | |
| Dynavax Technologies Corporation | $46.99 | 2023-2024 | Heplisav-B |
| Sumitomo Pharma America, INC. | $40.70 | 2025 | Gemtesa |
| Boston Scientific Corporation | $38.40 | 2024 | Bodyguardian |
| Phathom Pharmaceuticals, INC. | $32.73 | 2024-2025 | Voquezna |
| Hikma Pharmaceuticals USA | $25.77 | 2020 | |
| Axsome Therapeutics, INC. | $23.91 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $23.22 | 2025 | |
| Ibsa Pharma INC. | $20.43 | 2024 | Licart, Tirosint |
| Dexcom, INC. | $20.40 | 2025 | Dexcom G6 Transmitter |
| Inari Medical, INC. | $19.20 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Biohaven Pharmaceuticals, INC. | $17.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.18 | 2019 | |
| Almatica Pharma LLC | $16.60 | 2025 | Teriparatide, Loreev Xr |
| Hologic Sales and Service, LLC | $16.48 | 2022 | |
| Fresenius Kabi USA, LLC | $15.42 | 2023 | Idacio |
| Linus Health, INC. | $15.32 | 2024 | Core Cognitive Evaluation |
| Teva Pharmaceuticals USA, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Garrity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.